Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data

被引：0

作者：

Younan, Helen-Cara ^{[1
]}

Zhang, Shuai ^{[2
]}

Monroy, Maria ^{[3
]}

Almusarhed, Manar ^{[4
]}

Julve, Max ^{[5
]}

Roy, Debashree ^{[4
]}

Toghey, Sopozme ^{[2
]}

Ahmed, Zartaj ^{[2
]}

Slater, Stephanie ^{[5
]}

Altharwane, Shaymaa ^{[4
]}

Giorgiou, Alex ^{[3
]}

Ghosh, Sharmistha ^{[3
]}

Gennatas, Spyridon ^{[3
]}

Karapanagiotou, Eleni ^{[3
]}

Montes, Ana ^{[3
]}

Pintus, Elias ^{[3
]}

Spicer, James ^{[3
]}

Shah, Riyaz ^{[2
]}

Ahmed, Samreen ^{[4
]}

Newsom-Davis, Tom ^{[5
]}

Mohammed, Waleed ^{[1
]}

Power, Danielle ^{[1
]}

Evans, Joanne ^{[1
]}

Hatcher, Olivia ^{[1
]}

Lakhani, Amish ^{[1
]}

Samani, Amit ^{[1
]}

Josephs, Debra ^{[3
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, London, England

[2] Maidstone & Tunbridge Wells NHS Trust, Tunbridge Wells, Kent, England

[3] Guys & St Thomas NHS Fdn Trust, London, England

[4] Univ Hosp Leicester NHS Trust, Leicester, Leics, England

[5] Chelsea & Westminster Hosp NHS Fdn Trust, London, England

来源：

LUNG CANCER | 2022年 / 165卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S32 / S32

页数：1

共 50 条

[1] Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer
Galan, Rocio Jimenez
Prado-Mel, Elena
de Sotomayor, Maria Alvarez
Martin, Laila Abdel-Kader
BIOLOGY-BASEL, 2023, 12 (02):
[2] Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
Velcheti, Vamsidhar
Hu, Xiaohan
Yang, Lingfeng
Pietanza, M. Catherine
Burke, Thomas
FRONTIERS IN ONCOLOGY, 2022, 12
[3] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
Velcheti, Vamsidhar
Chandwani, Sheenu
Chen, Xin
Pietanza, M. Catherine
Burke, Thomas
CANCER RESEARCH, 2019, 79 (13)
[4] Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre
Fletcher, J.
Mullally, W. J.
Berman, C.
Ladwa, R.
Xu, W.
O'Byrne, K.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S628 - S629
[5] REAL-WORLD EFFECTIVENESS AND SAFETY OF FIRST-LINE PEMBROLIZUMAB MONOTHERAPY FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Kamboj, G.
Radotra, A.
Barman, P.
Dongare, S.
Aggarwal, S.
Rathi, H.
VALUE IN HEALTH, 2024, 27 (06) : S398 - S398
[6] Age-Related Outcomes of First-Line Pembrolizumab in a Real-World Non-Small-Cell Lung Cancer (NSCLC) Cohort
Dolter, S.
Grosjean, H.
Meyers, D.
Javizian, O.
Stukalin, I.
Goutam, S.
Morris, D.
Bebb, D. G.
Pabani, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S290 - S290
[7] Real-world efficacy of first-line therapy in wild-type non-small cell lung cancer (NSCLC) patients with brain metastases
Kong, B.
Wei, J.
Smith, S.
Chan, W. Y.
Harden, S. V.
Khou, V.
Alexander, M.
Brown, C.
Itchins, M.
Lee, J.
Mersiades, A.
Gray, L.
Boyer, M.
Pavlakis, N.
Clarke, S.
Jayamanne, D.
Kao, S. C-H.
ANNALS OF ONCOLOGY, 2022, 33 : S1577 - S1578
[8] Pembrolizumab for the first-line treatment of non-small cell lung cancer
Ninomiya, Kiichiro
Hotta, Katsuyuki
EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
[9] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
Kuzminin, A.
Minatta, N.
Bluthgen, M.
Rizzo, M.
Naveira, M.
Wainsztein, V.
Lupinacci, L.
Rizzi, M.
Faura, M.
Perfetti, A.
Recondo, G., Jr.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
[10] Effectiveness and safety of pembrolizumab as first-line treatment for non-small cell lung cancer in real clinical practice
Romero-Ventosa, Elena Yaiza
Garcia-Beloso, Nerea
Lopez-Lopez, Aida
Martinez-Lopez-de-Castro, Noemi
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,

← 1 2 3 4 5 →